Flexmore

Atropa Belladonna, Bryonia Alba Root, Colchicum Autumnale Bulb, Guaiacum Officinale Resin, Kalmia Latifolia Leaf, Rhododendron Tomentosum Leafy Twig, Ruta Graveolens Flowering Top, Tribasic Calcium Phosphate, Comfrey Root And Toxicodendron Pubescens Leaf


Hyland's
Human Otc Drug
NDC 54973-3397
Flexmore also known as Atropa Belladonna, Bryonia Alba Root, Colchicum Autumnale Bulb, Guaiacum Officinale Resin, Kalmia Latifolia Leaf, Rhododendron Tomentosum Leafy Twig, Ruta Graveolens Flowering Top, Tribasic Calcium Phosphate, Comfrey Root And Toxicodendron Pubescens Leaf is a human otc drug labeled by 'Hyland's'. National Drug Code (NDC) number for Flexmore is 54973-3397. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Flexmore drug includes Atropa Belladonna - 30 [hp_X]/1 Bryonia Alba Root - 30 [hp_X]/1 Colchicum Autumnale Bulb - 12 [hp_X]/1 Comfrey Root - 30 [hp_X]/1 Guaiacum Officinale Resin - 12 [hp_X]/1 Kalmia Latifolia Leaf - 12 [hp_X]/1 Rhododendron Tomentosum Leafy Twig - 30 [hp_X]/1 Ruta Graveolens Flowering Top - 12 [hp_X]/1 Toxicodendron Pubescens Leaf - 30 [hp_X]/1 Tribasic Calcium Phosphate - 6 [hp_X]/1 . The currest status of Flexmore drug is Active.

Drug Information:

Drug NDC: 54973-3397
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Flexmore
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Atropa Belladonna, Bryonia Alba Root, Colchicum Autumnale Bulb, Guaiacum Officinale Resin, Kalmia Latifolia Leaf, Rhododendron Tomentosum Leafy Twig, Ruta Graveolens Flowering Top, Tribasic Calcium Phosphate, Comfrey Root And Toxicodendron Pubescens Leaf
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Hyland's
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ATROPA BELLADONNA - 30 [hp_X]/1
BRYONIA ALBA ROOT - 30 [hp_X]/1
COLCHICUM AUTUMNALE BULB - 12 [hp_X]/1
COMFREY ROOT - 30 [hp_X]/1
GUAIACUM OFFICINALE RESIN - 12 [hp_X]/1
KALMIA LATIFOLIA LEAF - 12 [hp_X]/1
RHODODENDRON TOMENTOSUM LEAFY TWIG - 30 [hp_X]/1
RUTA GRAVEOLENS FLOWERING TOP - 12 [hp_X]/1
TOXICODENDRON PUBESCENS LEAF - 30 [hp_X]/1
TRIBASIC CALCIUM PHOSPHATE - 6 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jun, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 09 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Hyland's
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:WQZ3G9PF0H
T7J046YI2B
993QHL78E6
M9VVZ08EKQ
N0K2Z502R6
79N6542N18
877L01IZ0P
N94C2U587S
6IO182RP7A
91D9GV0Z28
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
54973-3397-11 BOTTLE, PLASTIC in 1 CARTON (54973-3397-1) / 50 TABLET in 1 BOTTLE, PLASTIC01 Jun, 2019N/ANo
54973-3397-24 TABLET in 1 PACKET (54973-3397-2)01 Jun, 2019N/AYes
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Joint pain stiff & swollen joints rheumatic pain

Product Elements:

Flexmore atropa belladonna, bryonia alba root, colchicum autumnale bulb, guaiacum officinale resin, kalmia latifolia leaf, rhododendron tomentosum leafy twig, ruta graveolens flowering top, tribasic calcium phosphate, comfrey root and toxicodendron pubescens leaf lactose monohydrate anhydrous lactose acacia atropa belladonna atropa belladonna bryonia alba root bryonia alba root colchicum autumnale bulb colchicum autumnale bulb guaiacum officinale resin guaiacum officinale resin kalmia latifolia leaf kalmia latifolia leaf rhododendron tomentosum leafy twig rhododendron tomentosum leafy twig tribasic calcium phosphate phosphate ion comfrey root comfrey root toxicodendron pubescens leaf toxicodendron pubescens leaf ruta graveolens flowering top ruta graveolens flowering top

Indications and Usage:

Uses ■ help temporarily relieves the symptoms of minor arthritis pain, including: ■ minor swelling or stiffness ■ joint, neck or back pain ■ muscular cramping associated with minor rheumatic pain

Warnings:

Warnings stop use and ask a doctor if ■ pain gets worse or lasts more than 7 days. ■ new symptoms occur. ■ redness or swelling is present. if pregnant or breastfeeding ask a health professional before use. keep out of reach of children.

Dosage and Administration:

Directions ■ use as directed. adults and children 12 years and over at onset of symptoms, dissolve 2-3 tablets under tongue every 4 hours until relieved. children under 12 years of age ask a doctor before use.

Stop Use:

Stop use and ask a doctor if ■ pain gets worse or lasts more than 7 days. ■ new symptoms occur. ■ redness or swelling is present.

Package Label Principal Display Panel:

Principal display panel hyland's naturals™ flexmore ® arthritis pain relief* joint pain stiff & swollen joints rheumatic pain 50 quick-dissolving tablets homeopathic carton

Further Questions:

Questions? www.hylands.com or care@hylands.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.